| 7.76 -0.55 (-6.62%) | 08-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.05 | 1-year : | 15.95 |
| Resists | First : | 11.17 | Second : | 13.65 |
| Pivot price | 8.98 |
|||
| Supports | First : | 7.15 | Second : | 5.94 |
| MAs | MA(5) : | 8.08 |
MA(20) : | 9.24 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 16.8 |
D(3) : | 16.9  |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 18.79 | Low : | 7.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CNXU ] has closed above bottom band by 16.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 9.01 - 9.06 | 9.06 - 9.1 |
| Low: | 7.51 - 7.56 | 7.56 - 7.6 |
| Close: | 7.53 - 7.61 | 7.61 - 7.68 |
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
Mon, 03 Aug 2026
Top Conexeu Sciences (CNXU) Competitors 2026 - MarketBeat
Mon, 03 Aug 2026
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison - Yahoo Finance
Thu, 30 Jul 2026
Conexeu Sciences (CNXU) logs $62,725 Rule 506(b) equity issuance for services - Stock Titan
Wed, 15 Jul 2026
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. - PR Newswire
Tue, 14 Jul 2026
CNXU Stock Price and Chart — NASDAQ:CNXU - tradingview.com
Thu, 09 Jul 2026
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 40.9 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -22.39 |
| PEG Ratio | 0 |
| Price to Book value | 22.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -46.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|